MoleMate Skin Imaging System – Available Now in US Through “Innovator’s Program”
MoleMate™ Skin Imaging System – Available Now in US Through “Innovator’s Program”
No Risk, 30-day FREE trial and up to $800 off cost of device
MISSISSAUGA, ON, Oct. 3, 2011 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy and light imaging systems, announced today the MoleMate™ Innovator’s Program. MoleMate, the unique FDA approved skin imaging system, previously only sold in the UKand Australia, is now available for sale in the US. The application process has also begun for Health Canadaapproval. MoleMate uses a hand-held device designed for office use that utilizes light to view beneath suspicious moles in a pain free, non-invasive manner, creating images for physicians to evaluate moles and lesions often eliminating the need for skin biopsies resulting in less pain, scarring, and expense. Physicians interested in learning more should contact their local representative on the web at http://simsys-molemate.com.
About MoleMate Innovator’s Program
MoleMate Innovator’s Program is marketed for the innovators in medicine who are the first to adopt leading edge scientific knowledge to allow them to experience first hand the benefits and advantages this technology brings to their clinical practice. The MoleMate Innovator’s Program offers a no risk, free imaging system for 30 days to evaluate the innovative features of this breakthrough technology. The MoleMate Innovator’s Program participants who enter the program in October will also be eligible for up to an $800 discount on the purchase of a system. The cost of a complete system ranges from $5,000 (MoleMate) to $10,000 per system, for SIMSYS, which contains a robust data management system as well as advanced imaging capabilities, including Mole Mapping (available in 2012). http://simsys-molemate.com/2011/09/29/introductory-offer-on-simsys-molemate-skin-imaging-system-no-risk-30-day-free-trial-and-up-to-800-discount-on-device/
For the first time, physicians can see within seconds what lies below suspicious moles using an FDA approved, hand-held, sophisticated light based device. Designed for busy offices, MoleMate improves the ability of the physician to identify a range of skin conditions from malignant melanoma or basal cell carcinoma to Seb K, in a non-invasive, pain-free manner. http://simsys-molemate.com
“Physicians around the world now have begun to realize the value in MoleMate. The technology integrates easily into the patient workflow, is relatively inexpensive, and the training CD which is included free with every unit can be completed successfully in less than 2 hours,” stated Steve Guillen, President and CEO of MedX Health.
Physicians in the MoleMate Innovator’s Program receive:
| - | Scope and matching fluid |
| - | MoleMate and SIMSYS software |
| - | 90 minute training CD |
| - | Free IT support |
| - | Up to $800 discount on purchase |
MoleMate
A powerful new tool to measure and characterize pigmented moles/lesions up to 2mm below the epidermis, providing five (5) unique views including a digital dermoscopic view and the only system that allows full color visualization of the position, spatial distribution, and concentration of the epidermal pigment, dermal pigment, blood, and collagen.
SIMSYS
At the same time, physicians in the MoleMate Innovator’s Program will also be able to compare the enhanced version, SIMSYS, with its sophisticated data management system, and advanced visualization tools, including Mole Mapping (available in 2012).
Many physicians who have used either MoleMate or SIMSYS have outlined a number of key benefits for themselves and their patients:
| Practice Friendly | Patient Friendly | ||
| - | Raises the practice profile | - | Non-invasive, pain free, fewer scars |
| - | Easily incorporates into patient workflow | - | Clear, concise patient reports |
| - | Easy to learn technology | - | On screen views enhance patient/MD consultation |
| - | Quickly identifies treatable conditions resulting in fewer biopsies | - | Fewer biopsies, no delay in results |
| - | Operates on all PC and MAC computers | ||
| - | Integrates easily into all EMR systems |
“We decided to purchase MoleMate to assist with patient reassurance and minimize excisions. We chose MoleMate because it provides clear imagery, is easy to show patients and explain and allows us to keep a record.”
― Dr. James, Queensland,Australia
US Launch Underway
MedX Health has a direct sales team of 30 associates in addition to 4 regional specialty Distributors calling on dermatologists and primary care physicians in the US, representing a $1 Billon market opportunity.
MoleMate and SIMSYS are currently the only FDA approved devices with this breakthrough technology available for sale in theUS.
MoleMate Innovator’s Program
Physicians wishing to become part of the MoleMate Innovator’s Program, and receive a free scope, software and training CD for 30 days should email a request to siascopy@medxhealth.com, or visit the MoleMate/SIMSYS website at http://simsys-molemate.com.
Corporate Partners
Proctor & Gamble, LenioMed Ltd., and ScreenCancer, Inc., are research and commercial partners that are funding the expansion of the underlying technology into new consumer and wound care markets.
About MedX Health Corp.
MedX is a twelve (12) year old Canadian company, headquartered in Mississauga, Ontario (Toronto), and is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technologies for use in numerous medical settings, including rehab/chiropractic, dental, wound care, and veterinary medicine, providing patients with drug free and non-invasive treatment of tissue damage and pain. MedX laser and light products are FDA approved, Health Canadacleared, and CE Mark approved for use in North Americaas well as the European Union. For a complete profile of MedX Health Corp. and its products visit www.medxhealth.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.
For further information:
Investors/IR/PR:
Steve Guillen
President, Chief Executive Officer and Director
MedX Health Corp. info@medxhealth.com
Phone: (905) 670-4428
